Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
- PMID: 10888881
- DOI: 10.1038/77083
Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
Abstract
Allelic loss at the short arm of chromosome 3 is one of the most common and earliest events in the pathogenesis of lung cancer, and is observed in more than 90% of small-cell lung cancers (SCLCs) and in 50-80% of non-small-cell lung cancers (NSCLCs). Frequent and early loss of heterozygosity and the presence of homozygous deletions suggested a critical role of the region 3p21.3 in tumorigenesis and a region of common homozygous deletion in 3p21.3 was narrowed to 120 kb (ref. 5). Several putative tumour-suppressor genes located at 3p21 have been characterized, but none of these genes appear to be altered in lung cancer. Here we describe the cloning and characterization of a human RAS effector homologue (RASSF1) located in the 120-kb region of minimal homozygous deletion. We identified three transcripts, A, B and C, derived from alternative splicing and promoter usage. The major transcripts A and C were expressed in all normal tissues. Transcript A was missing in all SCLC cell lines analysed and in several other cancer cell lines. Loss of expression was correlated with methylation of the CpG-island promoter sequence of RASSF1A. The promoter was highly methylated in 24 of 60 (40%) primary lung tumours, and 4 of 41 tumours analysed carried missense mutations. Re-expression of transcript A in lung carcinoma cells reduced colony formation, suppressed anchorage-independent growth and inhibited tumour formation in nude mice. These characteristics indicate a potential role for RASSF1A as a lung tumour suppressor gene.
Similar articles
-
Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.Oncogene. 2003 Mar 13;22(10):1580-8. doi: 10.1038/sj.onc.1206243. Oncogene. 2003. PMID: 12629521
-
The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas.Oncogene. 2001 Jun 14;20(27):3563-7. doi: 10.1038/sj.onc.1204469. Oncogene. 2001. PMID: 11429703
-
RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.Oncogene. 2001 Nov 8;20(51):7573-7. doi: 10.1038/sj.onc.1204968. Oncogene. 2001. PMID: 11709729
-
Molecular genetics of small cell lung carcinoma.Semin Oncol. 2001 Apr;28(2 Suppl 4):3-13. Semin Oncol. 2001. PMID: 11479891 Review.
-
Methylation of the RASSF1A gene in human cancers.Biol Chem. 2002 Jun;383(6):907-14. doi: 10.1515/BC.2002.097. Biol Chem. 2002. PMID: 12222680 Review.
Cited by
-
Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis.Cancer Res. 2012 Aug 1;72(15):3817-3827. doi: 10.1158/0008-5472.CAN-11-3343. Epub 2012 Jun 18. Cancer Res. 2012. PMID: 22710434 Free PMC article.
-
RASSF1A Signaling in the Heart: Novel Functions beyond Tumor Suppression.Mol Biol Int. 2012;2012:154283. doi: 10.1155/2012/154283. Epub 2012 Apr 10. Mol Biol Int. 2012. PMID: 22577551 Free PMC article.
-
A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma.Cancer Res. 2012 May 1;72(9):2206-17. doi: 10.1158/0008-5472.CAN-11-2906. Epub 2012 Mar 2. Cancer Res. 2012. PMID: 22389451 Free PMC article.
-
The Role of Epigenetic Mechanisms in the Pathogenesis of Hepatitis C Infection.Biomolecules. 2024 Aug 10;14(8):986. doi: 10.3390/biom14080986. Biomolecules. 2024. PMID: 39199374 Free PMC article. Review.
-
RASSF1A and the rs2073498 Cancer Associated SNP.Front Oncol. 2011 Dec 28;1:54. doi: 10.3389/fonc.2011.00054. eCollection 2011. Front Oncol. 2011. PMID: 22649770 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases